Pierre Miossec

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3966369/publications.pdf

Version: 2024-02-01

198 papers	16,767 citations	19608 61 h-index	15683 125 g-index
215	215	215	17877
all docs	docs citations	times ranked	citing authors

DIEDDE MIOSSEC

#	Article	IF	CITATIONS
1	Interleukin-17 and Type 17 Helper T Cells. New England Journal of Medicine, 2009, 361, 888-898.	13.9	1,285
2	Targeting IL-17 and TH17 cells in chronic inflammation. Nature Reviews Drug Discovery, 2012, 11, 763-776.	21.5	1,098
3	Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis and Rheumatism, 1999, 42, 963-970.	6.7	916
4	Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmunity Reviews, 2014, 13, 668-677.	2.5	751
5	Zinc and its role in immunity and inflammation. Autoimmunity Reviews, 2015, 14, 277-285.	2.5	531
6	Th17 Cells. American Journal of Pathology, 2012, 181, 8-18.	1.9	505
7	IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends in Molecular Medicine, 2016, 22, 230-241.	3.5	333
8	Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. Journal of Immunology, 1998, 161, 409-14.	0.4	327
9	Brief Report: Inhibition of interleukinâ€6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 2499-2503.	6.7	302
10	IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Research, 2001, 3, 168.	2.0	296
11	Th1/Th2 cytokine balance in arthritis. Arthritis and Rheumatism, 1997, 40, 2105-2115.	6.7	291
12	IL-17 as a future therapeutic target for rheumatoid arthritis. Nature Reviews Rheumatology, 2009, 5, 549-553.	3.5	286
13	Classical and Paradoxical Effects of TNF-α on Bone Homeostasis. Frontiers in Immunology, 2014, 5, 48.	2.2	286
14	Interferon gamma inhibits interleukin 10 production by monocytes Journal of Experimental Medicine, 1993, 177, 523-527.	4.2	276
15	IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. Journal of Clinical Investigation, 2000, 105, 1697-1710.	3.9	272
16	IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. Journal of Immunology, 1999, 162, 1246-51.	0.4	271
17	CONTRIBUTION OF INTERLEUKIN 17 TO SYNOVIUM MATRIX DESTRUCTION IN RHEUMATOID ARTHRITIS. Cytokine, 2000, 12, 1092-1099.	1.4	257
18	Interleukin-17 in rheumatoid arthritis: If T cells were to contribute to inflammation and destruction through synergy. Arthritis and Rheumatism, 2003, 48, 594-601.	6.7	256

#	Article	IF	CITATIONS
19	Enhancing Effect of IL-1, IL-17, and TNF-α on Macrophage Inflammatory Protein-3α Production in Rheumatoid Arthritis: Regulation by Soluble Receptors and Th2 Cytokines. Journal of Immunology, 2001, 167, 6015-6020.	0.4	246
20	Selected cytokine pathways in rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 365-383.	2.8	236
21	IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infection, 2009, 11, 625-630.	1.0	205
22	Anatomic Localization of Immature and Mature Dendritic Cells in an Ectopic Lymphoid Organ: Correlation with Selective Chemokine Expression in Rheumatoid Synovium. Journal of Immunology, 2002, 168, 5333-5341.	0.4	199
23	Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Annals of the Rheumatic Diseases, 2018, 77, 523-532.	0.5	191
24	The combination of tumor necrosis factor ? blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis and Rheumatism, 2001, 44, 1293-1303.	6.7	186
25	Rheumatoid Inflammatory T-Cell Clones express mostly Th1 but also Th2 and Mixed (Th0-Like) Cytokine Patterns. Scandinavian Journal of Immunology, 1993, 38, 75-82.	1.3	172
26	The role of T cells in rheumatoid arthritis: new subsets and new targets. Current Opinion in Rheumatology, 2007, 19, 284-288.	2.0	160
27	Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Annals of the Rheumatic Diseases, 2011, 70, 727-732.	0.5	157
28	Low levels of interleukinâ€4 and high levels of transforming growth factor β in rheumatoid synovitis. Arthritis and Rheumatism, 1990, 33, 1180-1187.	6.7	154
29	Genome-Wide Comparison between IL-17A- and IL-17F-Induced Effects in Human Rheumatoid Arthritis Synoviocytes. Journal of Immunology, 2009, 182, 3112-3120.	0.4	152
30	The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Annals of the Rheumatic Diseases, 2005, 65, 905-909.	0.5	138
31	Physiopathology of haemophilic arthropathy. Haemophilia, 2008, 14, 3-9.	1.0	134
32	Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. European Journal of Immunology, 2014, 44, 339-347.	1.6	132
33	IL-17RA and IL-17RC Receptors Are Essential for IL-17A-Induced ELR+ CXC Chemokine Expression in Synoviocytes and Are Overexpressed in Rheumatoid Blood. Journal of Immunology, 2008, 180, 655-663.	0.4	129
34	Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Annals of the Rheumatic Diseases, 2012, 71, 768-776.	0.5	126
35	IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes and Immunity, 2001, 2, 222-228.	2.2	122
36	Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. Arthritis and Rheumatism, 2004, 50, 199-208.	6.7	117

#	Article	IF	CITATIONS
37	The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium Journal of Clinical Investigation, 1995, 95, 456-463.	3.9	116
38	RANK and RANKL expression as markers of dendritic cell-t cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis and Rheumatism, 2005, 52, 2307-2312.	6.7	112
39	Interleukin-17 in fashion, at last: Ten years after its description, its cellular source has been identified. Arthritis and Rheumatism, 2007, 56, 2111-2115.	6.7	112
40	Effects of Interleukin 17 on the cardiovascular system. Autoimmunity Reviews, 2017, 16, 984-991.	2.5	109
41	IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. Frontiers in Medicine, 2018, 5, 364.	1.2	108
42	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 2019, 55, 100946.	5.0	103
43	Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles. Nature Reviews Rheumatology, 2016, 12, 703-715.	3.5	100
44	Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis and Rheumatism, 1994, 37, 1715-1722.	6.7	96
45	Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells. Frontiers in Immunology, 2014, 5, 425.	2.2	94
46	Interleukin-17 increases the effects of IL- $1\hat{l}^2$ on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. Journal of Neuroimmunology, 2003, 137, 125-133.	1.1	92
47	An update on the cytokine network in rheumatoid arthritis. Current Opinion in Rheumatology, 2004, 16, 218-222.	2.0	83
48	The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nature Reviews Rheumatology, 2019, 15, 747-757.	3.5	78
49	Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone, 1999, 24, 381-385.	1.4	77
50	Systemic effects of IL-17 in inflammatory arthritis. Nature Reviews Rheumatology, 2019, 15, 491-501.	3.5	77
51	Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. Journal of Biotechnology, 2004, 114, 121-124.	1.9	76
52	Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open, 2017, 3, e000284.	1.8	76
53	Role of Interleukin 17 in Arthritis Chronicity through Survival of Synoviocytes via Regulation of Synoviolin Expression. PLoS ONE, 2010, 5, e13416.	1.1	76
54	Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Research, 2004, 6, R190.	2.0	74

#	Article	IF	CITATIONS
55	Expression of tollâ€like receptor 3 and tollâ€like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis and Rheumatism, 2010, 62, 2144-2151.	6.7	74
56	Bone marrow–derived and synoviumâ€derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: Contribution to the chronicity of rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 2147-2157.	6.7	74
57	The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Annals of the Rheumatic Diseases, 2006, 65, 342-347.	0.5	73
58	Importance of Correlation between Gene Expression Levels: Application to the Type I Interferon Signature in Rheumatoid Arthritis. PLoS ONE, 2011, 6, e24828.	1.1	73
59	Combination of the pro-inflammatory cytokines IL-1, TNF-\$alpha; and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-\$kappa;B in osteoblast-like cells*1. Cytokine, 2004, 26, 169-177.	1.4	67
60	Medical applications of Cu, Zn, and S isotope effects. Metallomics, 2016, 8, 1056-1070.	1.0	66
61	Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. Journal of Pathology, 2004, 204, 28-38.	2.1	63
62	Biological Applications and Toxicity Minimization of Semiconductor Quantum Dots. Trends in Biotechnology, 2020, 38, 163-177.	4.9	63
63	mRNA Quantification of T-bet, GATA-3, IFN-γ, and IL-4 Shows a Defective Th1 Immune Response in the Peripheral Blood from Rheumatoid Arthritis Patients: Link with Disease Activity. Journal of Clinical Immunology, 2005, 25, 209-214.	2.0	61
64	IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Annals of the Rheumatic Diseases, 2011, 70, 341-348.	0.5	61
65	IL-17 and tumour necrosis factor α combination induces a HIF-1α-dependent invasive phenotype in synoviocytes. Annals of the Rheumatic Diseases, 2012, 71, 1393-1401.	0.5	61
66	Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. Arthritis Research, 2005, 7, R149.	2.0	60
67	Contribution of tumour necrosis factor and interleukin (IL) 1 to IL6 production, NF-ÂB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Annals of the Rheumatic Diseases, 2005, 64, 1257-1262.	0.5	59
68	Immature muscle precursors are a source of interferonâ€Î² in myositis: Role of Tollâ€like receptor 3 activation and contribution to HLA class I upâ€regulation. Arthritis and Rheumatism, 2012, 64, 533-541.	6.7	59
69	Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: Correlations with markers of inflammation and joint destruction. Arthritis and Rheumatism, 1998, 41, 1083-1089.	6.7	57
70	Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. Ecological Management and Restoration, 2011, 24, 299-304.	0.2	55
71	Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine, 2009, 46, 297-301.	1.4	54
72	Change in the Th1/Th2 Phenotype of Memory T-Cell Clones from Rheumatoid Arthritis Synovium. Scandinavian Journal of Immunology, 1999, 50, 1-9.	1.3	53

#	Article	IF	CITATIONS
73	Plasma Cell-Like Morphology of Th1-Cytokine-Producing Cells Associated with the Loss of CD3 Expression. American Journal of Pathology, 2004, 164, 409-417.	1.9	53
74	IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. Cytokine, 2007, 38, 157-164.	1.4	53
75	IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmunity Reviews, 2018, 17, 1176-1185.	2.5	53
76	Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at â^308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor. Arthritis and Rheumatism, 2008, 58, 1258-1263.	6.7	52
77	Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. Current Opinion in Rheumatology, 2020, 32, 57-63.	2.0	52
78	Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF- $\hat{l}\pm$ on endothelial cells. Annals of the Rheumatic Diseases, 2013, 72, 754-760.	0.5	49
79	Effect of treatment of rheumatoid arthritis with infliximab on IFNÂ, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Annals of the Rheumatic Diseases, 2004, 64, 415-418.	0.5	48
80	Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis and Rheumatism, 2006, 54, 2109-2118.	6.7	48
81	Cryoglobulins: An update on detection, mechanisms and clinical contribution. Autoimmunity Reviews, 2018, 17, 457-464.	2.5	47
82	High Levels of Neutralizing Autoantibodies Against ILâ€1α are Associated with a Better Prognosis in Chronic Polyarthritis: a Followâ€Up Study. Scandinavian Journal of Immunology, 1997, 46, 413-418.	1.3	46
83	Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Research and Therapy, 2010, 12, R143.	1.6	46
84	Interleukin-17 in Inflammatory Myopathies. Current Rheumatology Reports, 2012, 14, 252-256.	2.1	46
85	Differential Effects of IL-17A and TNF-α on Osteoblastic Differentiation of Isolated Synoviocytes and on Bone Explants from Arthritis Patients. Frontiers in Immunology, 2015, 6, 151.	2.2	46
86	Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. Arthritis Research and Therapy, 2016, 18, 148.	1.6	45
87	Cytokine-Induced Autoimmune Disorders. Drug Safety, 1997, 17, 93-104.	1.4	44
88	Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12RÂ2 inhibition. Annals of the Rheumatic Diseases, 2010, 69, 1562-1567.	0.5	44
89	IL-17 inhibits human Th1 differentiation through IL-12Rβ2 downregulation. Cytokine, 2009, 48, 226-230.	1.4	42
90	Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways. Clinical and Experimental Immunology, 2018, 193, 221-233.	1.1	41

#	Article	IF	CITATIONS
91	FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Annals of the Rheumatic Diseases, 2010, 69, 755-760.	0.5	40
92	Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis and Rheumatism, 2003, 48, 631-637.	6.7	39
93	Rheumatoid arthritis: still a chronic disease. Lancet, The, 2013, 381, 884-886.	6.3	37
94	Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells. Clinical and Experimental Immunology, 2016, 186, 64-74.	1.1	37
95	POTENTIAL CONTRIBUTION OF IL-17- PRODUCING TH1CELLS TO DEFECTIVE REPAIR ACTIVITY IN JOINT INFLAMMATION: PARTIAL CORRECTION WITH Th2-PROMOTING CONDITIONS. Cytokine, 2001, 13, 113-118.	1.4	36
96	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Annals of the Rheumatic Diseases, 2011, 70, 1713-1718.	0.5	36
97	Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Research and Therapy, 2008, 10, S2.	1.6	35
98	Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis. Joint Bone Spine, 2010, 77, 297-305.	0.8	35
99	Additive or Synergistic Interactions Between IL-17A or IL-17F and TNF or IL-1Î ² Depend on the Cell Type. Frontiers in Immunology, 2019, 10, 1726.	2.2	34
100	Enhancement of Adenovirus-Mediated Gene Delivery to Rheumatoid Arthritis Synoviocytes and Synovium by Fiber Modifications: Role of Arginine-Glycine-Aspartic Acid (RGD)- and Non-RGD-Binding Integrins. Journal of Immunology, 2005, 175, 7687-7698.	0.4	32
101	Interleukin 4, but not Interleukin 10, Regulates the Production of Inflammation Mediators by Rheumatoid Synoviocytes. Cytokine, 1995, 7, 176-183.	1.4	31
102	Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. Arthritis Research and Therapy, 2009, 11, 246.	1.6	30
103	A Feedback Loop between Inflammation and Zn Uptake. PLoS ONE, 2016, 11, e0147146.	1.1	30
104	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. Journal of Analytical Atomic Spectrometry, 2016, 31, 1002-1011.	1.6	30
105	Interleukin-17 and lupus: enough to be a target? For which patients?. Lupus, 2020, 29, 6-14.	0.8	30
106	A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1629-1631.	0.5	29
107	Differential effects of TNF- \hat{l} + and IL- $1\hat{l}^2$ on the control of metal metabolism and cadmium-induced cell death in chronic inflammation. PLoS ONE, 2018, 13, e0196285.	1.1	29
108	Blockade of bone morphogenetic protein signaling potentiates the pro-inflammatory phenotype induced by interleukin-17 and tumor necrosis factor- \hat{l} ± combination in rheumatoid synoviocytes. Arthritis Research and Therapy, 2015, 17, 192.	1.6	27

#	Article	IF	CITATIONS
109	Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-α and IL-17A induced osteoblastic differentiation. Bone, 2016, 87, 89-96.	1.4	27
110	Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting. Cellular and Molecular Immunology, 2021, 18, 860-865.	4.8	27
111	Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases. Nature Reviews Rheumatology, 2021, 17, 550-564.	3.5	27
112	Increased incidence of neutralizing autoantibodies against interleukin-1? (IL-1?) in nondestructive chronic polyarthritis. Journal of Clinical Immunology, 1996, 16, 283-290.	2.0	26
113	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 2016, 75, 1268-1271.	0.5	26
114	PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints. Nature Communications, 2017, 8, 146.	5.8	26
115	Interleukin-25 Produced by Synoviocytes Has Anti-inflammatory Effects by Acting As a Receptor Antagonist for Interleukin-17A Function. Frontiers in Immunology, 2017, 8, 647.	2.2	26
116	Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis. Arthritis Research, 2004, 6, R39.	2.0	25
117	Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years. Arthritis and Rheumatology, 2019, 71, 1904-1912.	2.9	25
118	Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1α specific inhibitor. Molecular Immunology, 1996, 33, 649-658.	1.0	24
119	Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2009, 68, 1197-1200.	0.5	24
120	A critical role for immature muscle precursors in myositis. Nature Reviews Rheumatology, 2013, 9, 438-442.	3.5	24
121	Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. Annals of the Rheumatic Diseases 2002 61, 730-733	0.5	23
122	Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis. Scientific Reports, 2017, 7, 2415.	1.6	23
123	Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cellular and Molecular Immunology, 2021, 18, 1644-1651.	4.8	23
124	Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. Journal of Clinical Immunology, 1998, 18, 399-403.	2.0	22
125	Diseases that may benefit from manipulating the Th17 pathway. European Journal of Immunology, 2009, 39, 667-669.	1.6	22
126	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	1.4	22

#	Article	IF	CITATIONS
127	IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells. Clinical and Experimental Immunology, 2019, 198, 111-120.	1.1	22
128	Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. Journal of Autoimmunity, 2022, 130, 102831.	3.0	21
129	Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFα therapy. Biologics: Targets and Therapy, 2008, 2, 663.	3.0	20
130	Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis. Current Opinion in Rheumatology, 2021, 33, 1-7.	2.0	20
131	Chemokines and dendritic cells in inflammatory myopathies: Figure 1. Annals of the Rheumatic Diseases, 2009, 68, 300-304.	0.5	19
132	Modeling of the effects of IL-17 and TNF-α on endothelial cells and thrombus growth. Comptes Rendus - Biologies, 2017, 340, 456-473.	0.1	19
133	Activation of the Peroxisome Proliferator–Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1252-1264.	2.9	18
134	Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts. Frontiers in Immunology, 2018, 9, 3170.	2.2	18
135	Cytokine response in inflammatory myopathies. Current Rheumatology Reports, 2007, 9, 286-290.	2.1	17
136	Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients. Journal of Clinical Medicine, 2019, 8, 751.	1.0	17
137	Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opinion on Drug Safety, 2022, 21, 223-239.	1.0	16
138	The Th17 Pathway in Vascular Inflammation: Culprit or Consort?. Frontiers in Immunology, 2022, 13, 888763.	2.2	16
139	Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1420-1422.	0.5	15
140	Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation. European Journal of Rheumatology, 2020, 7, S97-S98.	1.3	15
141	Improved Adenovirus Type 5 Vector-Mediated Transduction of Resistant Cells by Piggybacking on Coxsackie B-Adenovirus Receptor-Pseudotyped Baculovirus. Journal of Virology, 2009, 83, 6048-6066.	1.5	14
142	IL-17A and TNF-α Increase the Expression of the Antiapoptotic Adhesion Molecule Amigo-2 in Arthritis Synoviocytes. Frontiers in Immunology, 2016, 7, 254.	2.2	14
143	Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction. PLoS ONE, 2017, 12, e0188202.	1.1	14
144	Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features. Frontiers in Immunology, 2022, 13, 820046.	2.2	14

#	Article	IF	CITATIONS
145	Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 1800-1805.	6.7	12
146	T-cell clones from Th1, Th17 or Th1/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes. Cytokine, 2016, 88, 241-250.	1.4	12
147	Regulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation. PLoS ONE, 2017, 12, e0180879.	1.1	12
148	Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis. Autoimmunity, 2006, 39, 171-176.	1.2	11
149	Interleukinâ€17 and Th17 cells: From adult to juvenile arthritis—Now it is serious!. Arthritis and Rheumatism, 2011, 63, 2168-2171.	6.7	11
150	Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes. Frontiers in Immunology, 2016, 7, 509.	2.2	11
151	Anti-interleukin 1alpha autoantibodies. Annals of the Rheumatic Diseases, 2002, 61, 577-579.	0.5	10
152	Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study. Annals of the Rheumatic Diseases, 2012, 71, 1423-1424.	0.5	10
153	Live-stream characterization of cadmium-induced cell death using visible CdTe-QDs. Scientific Reports, 2018, 8, 12614.	1.6	10
154	Is undifferentiated spondyloarthritis a discrete entity? A debate. Autoimmunity Reviews, 2018, 17, 29-32.	2.5	9
155	Extensive Phenotype of Human Inflammatory Monocyte-Derived Dendritic Cells. Cells, 2021, 10, 1663.	1.8	9
156	The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases. Autoimmunity Reviews, 2022, 21, 103098.	2.5	9
157	A routine assay for the direct analysis of HLA-DR-related shared epitope and B27 alleles in chronic inflammatory arthritis. Journal of Immunological Methods, 2001, 256, 47-53.	0.6	8
158	Two phase kinetics of the inflammatory response from hepatocyte-peripheral blood mononuclear cell interactions. Scientific Reports, 2019, 9, 8378.	1.6	8
159	Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes. Frontiers in Immunology, 2019, 10, 2992.	2.2	8
160	Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 1998.	2.2	8
161	Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVIDâ€19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect?. Arthritis and Rheumatology, 2020, 72, 1963-1966.	2.9	7
162	Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2094622.	1.2	7

#	Article	IF	CITATIONS
163	Contribution of Hepatitis C Infection to a Large Cohort of Cryoglobulin-Positive Patients: Detection and Characteristics. Frontiers in Immunology, 2020, 11, 1183.	2.2	7
164	Practical Details for the Detection and Interpretation of Cryoglobulins. Clinical Chemistry, 2022, 68, 282-290.	1.5	7
165	New regulatory rules for clinical trials in the United States and the European Union: Key points and comparisons. Arthritis and Rheumatism, 2006, 54, 3735-3740.	6.7	5
166	Introduction: â€~Why is there persistent disease despite aggressive therapy of rheumatoid arthritis?'. Arthritis Research and Therapy, 2014, 16, 113.	1.6	5
167	IL-17, now an important target for treatment in arthritis. Joint Bone Spine, 2017, 84, 247-249.	0.8	5
168	Connectivity to other fields brings new ideas. Nature Reviews Rheumatology, 2018, 14, 65-66.	3.5	5
169	Kinase inhibition in rheumatoid arthritis: a big advance?. Lancet, The, 2013, 381, 429-431.	6.3	4
170	lgG subclasses in cryoglobulins: link to composition and clinical manifestations. Arthritis Research and Therapy, 2020, 22, 267.	1.6	4
171	A rapid semi automated method for DNA extraction from dried-blood spots: Application to the HLA-DR shared epitope analysis in rheumatoid arthritis. Journal of Immunological Methods, 2007, 328, 220-225.	0.6	3
172	Immunoregulation in Idiopathic Inflammatory Myopathies: From Dendritic Cells to Immature Regenerating Muscle Cells. Journal of Rheumatology, 2013, 40, 110-112.	1.0	3
173	Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels. International Journal of Molecular Sciences, 2021, 22, 11095.	1.8	3
174	Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 778480.	2.2	3
175	Translational medicine in RA—time for change. Nature Reviews Rheumatology, 2014, 10, 74-76.	3.5	2
176	Progress in the treatment of juvenile dermatomyositis. Lancet, The, 2016, 387, 627-628.	6.3	2
177	Interleukine 17 et l'inflammation chronique : de la découverte au ciblage thérapeutique. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 933-942.	0.0	2
178	Synoviocytes from pigmented villonodular synovitis are less sensitive to cadmium-induced cell death than synoviocytes from rheumatoid arthritis. Scientific Reports, 2022, 12, 3832.	1.6	2
179	Therapeutic targets in rheumatoid arthritis: More to come but which one(s) to select?. Drug Discovery Today Disease Mechanisms, 2005, 2, 327-330.	0.8	1
180	Cytokines and Autoimmune Diseases. Methods in Pharmacology and Toxicology, 2007, , 233-257.	0.1	1

#	Article	IF	CITATIONS
181	Drug treatments for rheumatoid arthritis: looking backwards to move forwards. BMJ, The, 2015, 350, h1192-h1192.	3.0	1
182	High oligoclonality of immunoglobulins in SARS-CoV2 positive patients. Annals of the Rheumatic Diseases, 2021, 80, 402-403.	0.5	1
183	Key points to consider for an improved detection and characterization of cryoglobulins. Autoimmunity Reviews, 2021, 20, 102948.	2.5	1
184	IL-17 as a contributor to inflammation and destruction in rheumatoid arthritis. , 2004, , 147-163.		1
185	IL-17 and Th17 cells, key players in arthritis. , 2009, , 89-101.		1
186	IL-17 and Th17 Cells in Rheumatoid Arthritis and Other Inflammatory Conditions. , 2013, , 233-242.		1
187	Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up. Frontiers in Medicine, 2020, 7, 556086.	1.2	1
188	TNFα et polyarthrite rhumatoÃ⁻de : compréhension du mode d'action et des effets secondaires des inhibiteurs thérapeutiques. Revue Du Rhumatisme (Edition Francaise), 2004, 71, S14-S21.	0.0	0
189	InmunopatologÃa de la artritis reumatoide. EMC - Aparato Locomotor, 2004, 37, 1-9.	0.1	0
190	Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments. , 2005, , 329-345.		0
191	Lupus et cytokines : compréhension des signes cliniques et identification des cibles thérapeutiques. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 126-129.	0.0	0
192	IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 247-251.	0.5	0
193	Biomarqueurs prédictifs de la réponse aux anti-TNF alpha dans la polyarthrite rhumatoÃ ⁻ de. Revue Du Rhumatisme (Edition Francaise), 2010, 77, 448-457.	0.0	0
194	Biomarqueurs et médecine personnalisée au cours de la polyarthrite rhumatoÃ ⁻ de : vers un changement historique. Revue Du Rhumatisme (Edition Francaise), 2011, 78, S154-S156.	0.0	0
195	Th17 Cells. , 2017, , 395-418.		0
196	Reply. Arthritis and Rheumatology, 2020, 72, 1956-1957.	2.9	0
197	IL-17 and Th17 cells in rheumatoid arthritis. , 2009, , 175-184.		0
198	Réactivation de la tuberculose au cours des traitements par inhibiteurs du TNF : compréhension et prévention. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 321-329.	0.0	0